Leerink Partnrs Reduces Earnings Estimates for Alkermes

Alkermes plc (NASDAQ:ALKS) – Equities researchers at Leerink Partnrs cut their FY2025 earnings estimates for Alkermes in a research note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now expects that the company will earn $1.33 per share for the year, down from their previous estimate of $1.38. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share. Leerink Partnrs also issued estimates for Alkermes’ FY2026 earnings at $1.52 EPS and FY2028 earnings at $1.30 EPS.

Several other research analysts also recently commented on ALKS. The Goldman Sachs Group lifted their price target on shares of Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. UBS Group raised Alkermes from a “sell” rating to a “neutral” rating and raised their price objective for the company from $21.00 to $38.00 in a research note on Tuesday, March 4th. Royal Bank of Canada assumed coverage on Alkermes in a research note on Thursday, March 13th. They issued a “sector perform” rating and a $40.00 target price for the company. Deutsche Bank Aktiengesellschaft lifted their price target on Alkermes from $40.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, March 27th. Finally, HC Wainwright restated a “neutral” rating and issued a $46.00 target price on shares of Alkermes in a report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.50.

Alkermes Trading Down 0.5 %

Shares of Alkermes stock opened at $27.05 on Wednesday. The business’s 50-day moving average price is $32.82 and its 200-day moving average price is $30.43. The firm has a market capitalization of $4.46 billion, a PE ratio of 12.47, a price-to-earnings-growth ratio of 2.20 and a beta of 0.39. Alkermes has a 12 month low of $22.90 and a 12 month high of $36.45.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%.

Insiders Place Their Bets

In related news, EVP Craig C. Hopkinson sold 144,419 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the transaction, the executive vice president now directly owns 57,875 shares in the company, valued at $2,056,298.75. This trade represents a 71.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.89% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alkermes

Institutional investors and hedge funds have recently made changes to their positions in the business. Ritholtz Wealth Management purchased a new stake in shares of Alkermes in the 1st quarter worth approximately $348,000. Fifth Third Bancorp grew its position in Alkermes by 54.4% during the 1st quarter. Fifth Third Bancorp now owns 1,479 shares of the company’s stock valued at $49,000 after purchasing an additional 521 shares during the last quarter. USA Financial Formulas bought a new stake in Alkermes during the 1st quarter valued at about $49,000. SG Americas Securities LLC grew its holdings in shares of Alkermes by 25.8% during the first quarter. SG Americas Securities LLC now owns 13,988 shares of the company’s stock valued at $462,000 after buying an additional 2,872 shares during the last quarter. Finally, Avanza Fonder AB bought a new stake in shares of Alkermes during the first quarter valued at approximately $266,000. Institutional investors own 95.21% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.